Author Interviews, Multiple Sclerosis / 13.11.2025

[caption id="attachment_71426" align="aligncenter" width="500"]multiple-sclerosis-ms-freepix Freepix image[/caption] Receiving a diagnosis of multiple sclerosis (MS) can be a life-altering event, bringing with it many questions about the future. MS is a condition of the central nervous system that disrupts communication between the brain and the body. Its effects vary widely from person to person, but recent progress in medical science offers more hope and better outcomes than ever before. The focus of care has expanded from simply managing symptoms to actively slowing the condition's progression and improving overall quality of life. Modern approaches to managing MS have transformed what it means to live with the condition. With a growing range of therapies, people with MS now have more opportunities to maintain their independence and continue participating in the activities they enjoy. These developments reflect a deeper recognition of how the disease works, leading to more targeted and convenient treatment plans.

Evolving Therapeutic Approaches

The main goal of modern MS treatments is to modify the course of the disease. These therapies, known as disease-modifying therapies (DMTs), work to reduce the frequency and severity of relapses, which are periods when symptoms flare up. Over the years, the administration of these treatments has become more convenient. While injectable medications were once the standard, many effective oral and infused options are now available, offering more flexibility for individuals. These newer medications are designed to target specific parts of the immune system that are involved in the MS process. This targeted approach helps to protect the brain and spinal cord from damage, slowing the advancement of disability associated with the condition. The availability of different types of DMTs allows healthcare professionals to tailor treatment plans to an individual's specific form of MS and their lifestyle.
Author Interviews, Brigham & Women's - Harvard, Infections, JAMA, Multiple Sclerosis, Neurological Disorders / 19.03.2024

MedicalResearch.com Interview with: [caption id="attachment_61454" align="alignleft" width="125"]Marianna Cortese, MD, PhDSenior Research Scientist Department of Nutrition Harvard T.H. Chan School of Public Health Boston, MA 02115 Dr. Cortese[/caption] Marianna Cortese, MD, PhD Senior Research ScientistDepartment of Nutrition Harvard T.H. Chan School of Public HealthBoston, MA 02115   MedicalResearch.com: What is the background for this study? Response: In a study published in Science in 2022, we reported compelling evidence that infection with the Epstein-Barr virus is the leading cause of Multiple Sclerosis. This is a follow-up study to investigate more in depth whether the antibody response to EBV is distinct in individuals with MS compared to individuals without MS and whether there is a part of EBV that the immune response is particularly targeting. For this purpose we assessed the immune response to all protein parts (peptides) of EBV and their association with MS. Previous studies could only look at parts of EBV and this is the first study looking at all EBV peptides. Antibodies to EBV (especially to a protein called EBNA1) are known to be overall higher in individuals with MS, so we also tested whether immune response overall or the immune response to specific EBV protein parts was more important. If the immune response to a specific EBV protein part (peptide) would be standing out or distinguishing individuals with MS, we hypothesized, it could point to a specific mechanism of how EBV may cause MS, i.e. it could point for example towards “molecular mimicry”, which is when antibodies targeting a pathogen start targeting a body-own structure (for example in the brain) which resembles the protein parts of the pathogen.
Author Interviews, Genetic Research, Infections, Neurological Disorders / 14.12.2022

MedicalResearch.com Interview with: [caption id="attachment_59834" align="alignleft" width="150"]Dr. Eli Hatchwell, MA MB BChir (Cantab) DPhil (Oxon) BA (OU)Chief Scientific Officer Population Bio UK, Inc. Begbroke Science Park Begbroke Hill Begbroke, Oxfordshire United Kingdom Dr. Hatchwell[/caption] Dr. Eli Hatchwell, MA MB BChir (Cantab) DPhil (Oxon) BA (OU) Chief Scientific Officer Population Bio UK, Inc. Begbroke Science Park Begbroke Hill Begbroke, Oxfordshire United Kingdom MedicalResearch.com: What is the background for this study? Response: Progressive Multifocal Leukoencephalopathy (PML) is a devastating condition that is associated with a number of clinical situations, including treatment with a variety of drugs. Of these, the best known is natalizumab (Tysabri), which is a very successful drug in the treatment of MS (multiple sclerosis). Only a small proportion of patients treated with natalizumab develop PML and this has always been a mystery. The study was based on a hypothesis that some individuals have an underlying susceptibility to developing PML, based on the presence of variants in genes that are important in the immune system. The study identified several of these variants.
Author Interviews, Multiple Sclerosis / 19.01.2022

MedicalResearch.com Interview with: [caption id="attachment_58674" align="alignleft" width="150"]Marcus Koch Dr. Koch[/caption] Marcus Koch MD PhD Associate Professor of Neurology Multiple Sclerosis Program University of Calgary MedicalResearch.com: What is the background for this study? Response: Primary progressive multiple sclerosis (PPMS) is the least common, but also the least treatable form of multiple sclerosis. PPMS does not react well to commonly used MS treatments. We believe that this is at least in part because PPMS is driven by other disease mechanisms. One disease mechanism that we believe is important in PPMS is microglial activation. Microglial cells are a type of cell in the brain and spinal cord that normally have beneficial functions, such as clearing debris or assisting repair after injury. In PPMS however, microglial cells are chronically active, and we believe that this chronic microglial activation contributes to tissue damage.